The inhibition of the mitogen-activated protein kinases signalling pathway through combined
use of BRAF and MEK inhibitors (BRAFi+ MEKi) represents an established therapeutic …

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors,
have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; …

Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …

PURPOSE To determine the safety and preliminary efficacy of selective combination
targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety …

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …

Early‐phase clinical trials using oral inhibitors of MEK, the mitogen‐activated protein kinase
kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1) …

Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK
inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic …

Purpose To investigate the clinical and morphologic characteristics of serous retinal
disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors …

Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous cellular signal
transduction pathways that regulate all aspects of life and are frequently altered in disease …

The proliferation of targeted anticancer agents over the last two decades has revolutionized
cancer treatment and improved survival in many previously refractory malignancies …